Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15542255 | 1.00 | KDM4E (0.42) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL18583477 | 1.00 | KDM4E (0.42) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL6128483 | 1.00 | KDM4E (0.42) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL14755201 | 1.00 | KDM4E (0.42) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL18787204 | 1.00 | KDM4E (0.42) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL24313644 | 0.86 | — | — | |
| SCHEMBL4194222 | 0.86 | — | — | |
| SCHEMBL3118447 | 0.86 | — | — | |
| SCHEMBL19228276 | 0.84 | EPHX1 (0.46) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL15139869 | 0.83 | KMT2A (0.50) | KDM4EMAPTKMT2AATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| CN-108366597-B | Substance mixture | 西姆莱斯有限公司 | 2022-09-02 | — | — | CN | claimed |
| EP-2906196-B1 | COSMETIC OR DERMATOLOGICAL PREPARATION FOR PROPHYLAXIS AND/OR TREATMENT OF ATOPIC DERMATITIS | BEIERSDORF AG (DE) | 2022-08-31 | — | — | EP | claimed |
| CN-114746089-A | Thiazolecarboxamide compounds and their use for the treatment of mycobacterial infections | 结核病药物开发全球联盟公司 | 2022-07-12 | — | — | CN | claimed |
| EP-3383200-B1 | COMPOSITIONS | SYMRISE AG (DE) | 2019-11-06 | — | — | EP | claimed |
| US-20190289886-A1 | SUBSTANCE MIXTURES | SYMRISE AG (DE) | 2019-09-26 | — | — | US | claimed |
| EP-3383200-A1 | SUBSTANCE MIXTURES | Symrise AG (DE) | 2018-10-10 | — | — | EP | claimed |
| EP-2867225-B1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2017-08-09 | — | — | EP | claimed |
| CN-104619698-B | Pyrrolidin derivatives and the purposes as complement pathway regulator thereof | 诺华股份有限公司 | 2016-08-31 | — | — | CN | claimed |
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2015-07-09 | — | — | US | claimed |
| EP-2867225-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | Novartis AG (CH) | 2015-05-06 | — | — | EP | claimed |
| WO-2014002054-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | claimed |
| EP-1606244-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | claimed |
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | claimed |
| WO-2004037769-A2 | CYCLOALKYLAMIDES AND THEIR THERAPEUTIC USE AS ANTIEPILEPTIC AND ANTICONVULSANT | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| WO-2003041649-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209858-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | KDM4E 3543/4885MAPT 383/4885KMT2A 3330/4885 |
| US-20040077618-A1 | Cycloalkylamides and their therapeutic applications | GAP43, SCN1B, GRIN2B | KDM4E 3543/4885MAPT 383/4885KMT2A 3330/4885 |
| US-20150190457-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS | C5, C9, TFPI | KDM4E 2549/4885MAPT 3243/4885KMT2A 4701/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | KDM4E 4591/4885MAPT 2789/4885KMT2A 4282/4885 |
| US-20190289886-A1 | SUBSTANCE MIXTURES | PNN, NISCH, HES1 | KDM4E 4364/4885MAPT 654/4885KMT2A 2251/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | KDM4E 4591/4885MAPT 2789/4885KMT2A 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.